VisionClearBlue Eye Clinic (Pty) Ltd is a proposed national network of comprehensive eye-care centres that will make specialist ophthalmology accessible in every South African province. Operating a hub-and-spoke model with one flagship clinic in each of the nine provinces, the Group will deliver the full continuum of eye care, examinations, consultations, cataract and laser surgery, retinal and glaucoma management, optical retail and AI-assisted screening. The Group seeks ZAR 450 million to build and equip the nine clinics, growing to over 300 employees, ~180,000 consultations and ~20,000 surgeries a year, and revenue exceeding R1.2 billion at a 20–25% EBITDA margin by Year 5.
|
R450m Funding sought |
9 Provincial clinics |
>R1.2bn Yr-5 revenue |
~300 Jobs created |
The opportunity
South African eye care is defined by a rare mismatch: very large, growing demand and a severe shortage of supply. The country has only around 324 to 400 ophthalmologists, roughly one-tenth the density of developed markets, concentrated in a few metros. It has never met the WHO target of 2,000 cataract surgeries per million per year, public waiting lists reach eighteen months, and rising diabetes is driving an epidemic of diabetic eye disease. The market is large, structurally growing and chronically under-served, and there is no dominant integrated national private eye-care network. VisionClearBlue is designed to fill that gap.
The strategy
VisionClearBlue will roll out nine flagship clinics in three phases, metros first, then secondary cities, then the remaining provinces, each an integrated one-stop centre combining ophthalmology, optometry, surgery and optical retail. Revenue is diversified across surgery (~48%), consultations (~22%), optical (~21%) and screening, corporate and telemedicine work. Standardised clinical protocols, modern diagnostics, AI-assisted screening, tele-ophthalmology and electronic records create a scalable, quality-controlled platform, and, critically, leverage the Group’s scarcest input, the ophthalmologist, across a national footprint.
Key findingSpecialist supply, not capital, is the binding constraint — and the model is built around it
The same shortage of ophthalmologists that creates the opportunity is the central execution challenge: VisionClearBlue must recruit and retain roughly eighteen specialists across nine provinces, including under-served rural ones, and lift each one’s throughput well above the norm to hit its surgical targets. The strategy, technology leverage, optometrist and nurse task-sharing, AI screening, tele-ophthalmology, visiting-surgeon rosters and high-throughput theatres, exists to make each scarce specialist go further. Investors should underwrite the recruitment and throughput plan as rigorously as the financials.
The capital request
The R450 million programme funds nine flagship clinics at R50 million each: medical equipment (R18m per clinic), laser systems (R12m), theatre equipment (R6m), an optical laboratory (R3m), furniture and fit-out (R5m), IT systems (R2m) and initial working capital (R4m). We propose funding this with approximately R280 million of equity and R170 million of development and equipment finance, a conservative ~38% gearing, with the debt drawn in phases as clinics are built, and a working-capital facility alongside to fund medical-aid receivables during the ramp.
The returns — and how to read them
On the sponsor’s targets, revenue exceeding R1.2 billion and a ~22% EBITDA margin by Year 5, exited at a conservative 8.5x EV/EBITDA, the plan delivers a five-year equity IRR in excess of 70% and a money multiple around 8.7x. These returns are exceptional, and they must be read with care: they are high precisely because the business is capital-light, a R450 million programme supporting a business generating some R267 million of EBITDA by Year 5. Such returns are achievable only if the aggressive rollout ramp and, above all, the specialist staffing are delivered. We therefore present them as a ceiling, and direct investors to the downside.
Analyst flagHow to read the returns — and the risks we do not smooth over
(1) The base-case returns are a ceiling, not a forecast. They assume nine clinics are built, staffed and ramped on plan; a combined-stress case, a 20% weaker ramp, a 20% lower margin and an 8x exit, still returns roughly 53%, cushioned by the light capital base. (2) Ophthalmologist supply is the binding risk. If the clinics cannot be staffed, especially in rural provinces, the revenue simply does not materialise, and no financial structure can compensate. (3) The early rollout is cash-consumptive, EBITDA is negative in Year 1 and debt-service cover is negative during the build, so a principal grace period, a reserve and a working-capital facility are structural requirements, not options.
Investment highlights
|
Highlight |
Why it matters |
|---|---|
|
Large, under-served market |
Cataract backlog, missed WHO targets, rising diabetic eye disease |
|
Severe supply shortage |
~324–400 ophthalmologists nationally — the opportunity and the moat |
|
Integrated, first-of-kind network |
One-stop surgery + consult + optical, standardised across 9 provinces |
|
Asset-backed security |
Equipped clinics (diagnostic, laser, theatre) as collateral |
|
Exceptional returns (a ceiling) |
Capital-light: R450m programme, ~R267m Year-5 EBITDA |
|
Resilient downside |
Combined-stress equity IRR still ~53% |
|
Genuine health impact |
Reduced avoidable blindness, access, ~300 skilled jobs |
Transaction summary
|
Item |
Detail |
|---|---|
|
Instrument |
Equity + development / equipment finance |
|
Total raise |
ZAR 450 million (9 clinics x R50m) |
|
Funding mix |
Equity R280m · Debt R170m (~38% gearing) |
|
Base-case equity IRR |
Exceptional (>70%) — read as a ceiling |
|
Combined-stress IRR |
~53% (ramp –20%, margin –20%, 8x exit) |
|
Year-5 revenue / EBITDA |
> R1.2bn / ~22% margin |
|
Network at scale |
9 clinics · ~180k consults · ~20k surgeries |
|
Target funders |
DFIs, impact & health investors, banks |
Why this plan is financeable
Four features make VisionClearBlue bankable. First, it is asset-backed: nine equipped clinics with diagnostic, laser and theatre equipment are tangible, collateral-grade assets. Second, the demand is structural and largely unmet, a cataract backlog, missed WHO targets, and a rising diabetic-eye-disease burden underwrite strong volumes for any operator that can deliver. Third, the model is diversified across surgery, optical and screening, and standardised for scale. Fourth, the development and impact case, accessible specialist eye care in under-served provinces, over 300 skilled jobs, diabetic-retinopathy and school screening, and reduced avoidable blindness, aligns precisely with the mandates of development-finance and impact-health investors. The Plan is candid about its two defining features, the specialist-supply constraint and the cash-consumptive rollout J-curve, and structures the financing and the operating model to manage both. The remainder of this Plan sets out the service model, the network and clinic economics, the market and competitive landscape, the implementation roadmap, the ESG framework, a candid risk assessment, and a complete three-statement financial model with rollout, exit-multiple and sensitivity analysis.